The worldwide biosimilars market will earn $16.03 billion in 2019, predicts a new visiongain report

LONDON - Sept. 3, 2015 - PRLog -- PHA0051 Press Release (Body Text) for Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2015-2025

Biosimilars market to generate $16bn in 2019, a new visiongain analysis predicts

A new report by visiongain forecasts the worldwide biosimilars market will earn $16.03 billion in 2019. That revenue prediction and others appear in Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2015-2025, published in June 2015.

The purpose of that investigation is to give sales forecasts and qualitative analysis of the biosimilars market. Those agents include follow-on biologics (FOB) and subsequent entry biologics (SEB). The study shows how those follow-on biopharmaceuticals, and companies producing them, fit into the overall biological drugs industry. That work assesses effects on the biologics market, present and future. Visiongain is a business information publisher and consultancy in London, UK. It produces analyses to help organisations understand potentials of industries and markets.

Arshad Ahad, a pharmaceutical industry analyst in visiongain, said: “Biologics are crucial for the treatment of many serious chronic disorders such as cancer, diabetes, hepatitis and autoimmune diseases. However those effective but highly complex therapies come at a price, with some treatments costing more than $75,000 a year. Biosimilars can offer the benefits of branded biologic therapies, but at a lower price, making them more affordable for individual patients, as well as entire nations in the face of restricted healthcare budgets.

“With patents for many blockbuster biologics set to expire over the next ten years, we predict the biosimilars market will grow rapidly between now and 2025, achieving high revenues. However it will face many challenges, including opposition from originator companies, expensive and lengthy development times and fragmentation of the market. Nevertheless, as the long-awaited approval of the first biosimilar in the US in 2015 shows, biosimilars are here to stay and their rise to prominence is just beginning.”

That updated investigation forecasts and discusses, from 2015 to 2025, the global biosimilars market, assessing its commercial potentials. The work also predicts revenues for market segments:

·         Monoclonal antibodies (mAbs) and fusion proteins (FPs)

·         Insulins

·         Granulocyte colony-stimulating factor (G-CSF)

·         Erythropoietin (EPO)

·         Interferons

·         Human growth hormone

·         Fertility hormones.

The report also gives forecasts and discussions from 2015 to 2025 for 12 leading national markets:

·         USA

·         Japan

·         Germany, France, UK, Italy and Spain

·         China, India, Russia, Brazil and South Korea.

That survey covers regulatory changes, other stimulating and restraining forces on the market, and prospects for companies. Those organisations include Sandoz, Pfizer, Amgen, Boehringer Ingelheim, Teva Pharmaceutical Industries and Dr. Reddy’s Laboratories. The analysis includes two interviews with authorities in that biopharmaceuticals industry.

Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2015-2025 adds to visiongain’s reports on industries and markets in healthcare. Together those studies analyse pharmaceuticals, medical devices, diagnostics and healthcare biotechnology, as well as outsourced research, manufacturing and sales.